← All Market Monitors SANOR About SANOR

GLP-1 Market Monitor

GLP-1 medicines are reshaping diabetes and weight-loss care, driving a race for customers, capital and market share. The SANOR GLP-1 Market Monitor tracks the companies, deals and commercial developments shaping this market.

Updated 23 September 2026

Market Size

$79.0bn

Annual global market size · 2025

Market Growth

+9.2%

Forecast annual growth (CAGR) · 2025–2035

Ticker Activity

22

Last 12 months

Deal Activity

7

Last 12 months

People in the GLP-1 Market

Portrait unavailable

Daniel Skovronsky

Chief Scientific & Product Officer

Daniel Skovronsky leads research and development at Eli Lilly and serves as president of Lilly Research Laboratories.

Portrait unavailable

David Ricks

Chair & Chief Executive Officer

David Ricks leads Eli Lilly as chair and chief executive officer.

Free Playbook

The Private Clinic Playbook

Grow revenue at each location and build a commercial model that can scale across a clinic group.

Sanor never sells your personal information. By providing this information you agree to Sanor’s Privacy Policy and Terms of Service.

Privacy Policy Terms of Service Disclaimer Sitemap

SANOR research follows the principles of ISO 20252:2019 and the ICC/ESOMAR International Code on Market, Opinion and Social Research and Data Analytics, and is conducted in line with our Independence Policy. Our published reports follow our Editorial Standards.

SANOR research is funded through advisory engagements and research licensing. We do not accept vendor sponsorship, paid placement, or advertising.

All publications are provided for general information only. They do not constitute medical, financial, or investment advice and do not account for the circumstances of any specific business or individual.

© 2026 SANOR Intelligence